Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the

E Scott Sills1, C D Drews, M Perloe

  • 1Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Atlanta Medical Center, Atlanta, Georgia, USA.

Insights

Young women with polycystic ovary syndrome (PCOS) show elevated plasminogen activator inhibitor (PAI-1) levels, suggesting potential hypofibrinolysis. These PAI-1 elevations persist even with normal insulin levels, indicating a distinct alteration in PCOS patients.

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Hematology

Background:

  • Polycystic ovary syndrome (PCOS) is associated with metabolic and reproductive disturbances.
  • Plasminogen activator inhibitor-1 (PAI-1) plays a key role in fibrinolysis.
  • Elevated PAI-1 is linked to insulin resistance and hyperandrogenism.

Purpose of the Study:

  • To investigate potential hypofibrinolytic tendencies in young PCOS patients.
  • To examine plasminogen activator inhibitor (PAI-1) system components in PCOS.
  • To determine if PAI-1 elevations persist independently of hyperinsulinism.

Main Methods:

  • Prospective, observational comparison study.
  • Inclusion of young women (<35 years) with PCOS (n=39) and controls (n=20).
  • Measurement of androgens, fasting insulin, PAI-1 antigen (Ag), PAI-1 activity, and tissue plasminogen activator (t-PA).

Main Results:

  • PCOS patients exhibited higher total testosterone and androstenedione levels.
  • Mean fasting insulin levels were significantly higher in PCOS women.
  • Elevated PAI-1 Ag, PAI-1 activity, and t-PA levels were observed in PCOS patients.
  • PAI-1 elevations persisted in PCOS even with normal or low insulin levels.

Conclusions:

  • This study quantifies distinct PAI-1 elevations in PCOS independent of hyperinsulinism.
  • The findings suggest a potential hypofibrinolytic state in PCOS.
  • Further research is needed to link this altered PAI-1 state to clinical outcomes and reproductive health.

Related Concept Videos

Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...